Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Publication year range
1.
Vaccine ; 22(19): 2470-9, 2004 Jun 23.
Article in English | MEDLINE | ID: mdl-15193411

ABSTRACT

The presence of aldehyde groups at C-23 and C-24 of the triterpen aglycon moiety was disclosed in 1H NMR spectra of both the Riedel de Haen saponin (R) (delta 9.336) and Quillaja saponaria QuilA saponin (delta 9.348). The sign of the C-28 acylated linked moiety (delta 176) was present in both saponins, while the delta 171 at C-28 (carboxy group) corresponding to the deacylated saponin, was only detected in the QuilA preparation, indicating 50% of hydrolysis of the ester moiety, probably due to the storage in aqueous solution. The normoterpen moiety was present in both saponins (signals at delta 14-18). The chemical removal of saponin glicidic moieties gave rise to their sapogenin fractions. Their 1H NMR spectra showed the presence of two signals (delta 9.226 and 9.236) for sapogenin R and two signals (delta 9.338 and 9.352) for the QuilA sapogenin. The intensity of the signals suggested two conformational isomers of sapogenin R in the ratio 53% of equatorial aldehyde group to 47% of axial aldehyde group, and two conformational isomers of QuilA sapogenin in the ratio 76% of equatorial aldehyde group to 24% of axial aldehyde group. The chemical treatment abolished the saponin slight in vivo toxicity, reduced their hemolytic potential, did not affect their aldehyde contents, but gave rise to an enriched axial aldehyde-containing sapogenin R with enhanced potential on antibody humoral response (anti-IgM, IgG, IgG1, IgG2a, IgG2b and IgG3) and to an enriched equatorial aldehyde-containing QuilA-sapogenin that induced a mainly cellular specific immune response (increased intradermal response to leishmanial antigen and IFNgamma sera levels) and effective protection against murine infection by L. donovani (77% reduction in liver parasitic load). Our results suggest that the Riedel de Haen saponin is probably a Quillaja saponaria saponin.


Subject(s)
Antigens, Protozoan/immunology , Leishmania donovani/immunology , Leishmaniasis, Visceral/prevention & control , Protozoan Vaccines/administration & dosage , Quillaja/chemistry , Saponins/administration & dosage , Adjuvants, Immunologic/administration & dosage , Animals , Mice , Protozoan Vaccines/immunology , Saponins/immunology , Saponins/therapeutic use
2.
Vaccine ; 20(27-28): 3277-84, 2002 Sep 10.
Article in English | MEDLINE | ID: mdl-12213397

ABSTRACT

Naturally exposed dogs of an endemic area were vaccinated with the fucose mannose ligand (FML) antigen of Leishmania donovani in formulation with QuilA saponin. The 100% of vaccinees were seropositive to FML and showed intradermal reaction to L. donovani lysate, 2 months after vaccination. The absorbency values and size of intradermal reaction were both significantly higher in vaccinees than in controls along a 3.5 years period (ANOVA, P<0.0001). The 25% of the control animals (two dogs on the first year and six dogs on the fourth year, respectively) and 5% of the vaccinees (one dog during the fourth year) developed clinical and fatal disease until the end of experiment. This difference was significant (chi(2)=3.93, P<0.05). This means that 95% protection against kala-azar was achieved in vaccinees, after FML-QuilA vaccination (80% of vaccine efficacy (VE)). Leishmania infection was also confirmed, 3.5 years after vaccination, in saline controls that showed positive polymerase chain reaction (PCR) for Leishmania DNA and FML-serology with no intradermal reaction. Higher seropositivities and intradermal reactions with no Leishmanial DNA were detected in vaccinees. The FML-QuilA vaccine induced a significant, long lasting and strong protective effect against canine kala-azar in the field.


Subject(s)
Dog Diseases/prevention & control , Leishmaniasis, Visceral/veterinary , Protozoan Vaccines/administration & dosage , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Protozoan/blood , Brazil , DNA, Protozoan/genetics , DNA, Protozoan/isolation & purification , Dog Diseases/immunology , Dog Diseases/parasitology , Dogs , Humans , Immunity, Cellular , Lectins/administration & dosage , Lectins/immunology , Leishmania donovani/genetics , Leishmania donovani/immunology , Leishmaniasis, Visceral/immunology , Leishmaniasis, Visceral/parasitology , Leishmaniasis, Visceral/prevention & control , Protozoan Proteins/administration & dosage , Protozoan Proteins/immunology , Quillaja Saponins , Saponins/administration & dosage
3.
Am J Trop Med Hyg ; 65(5): 510-7, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11716106

ABSTRACT

Brazil is the only country endemic for zoonotic visceral leishmaniasis (ZVL) that regularly conducts epidemiologic and prophylactic control programs that involve the treatment of human cases, insect vector control, and the removal of seropositive infected dogs. This report reviews 60 studies reporting data on the efficacy of these recommended control tools and concludes that in Brazil 1) eradication of the disease in Minas Gerais was achieved by the concomitant use of the three control methods, 2) although seropositivity by an immunofluorescent assay is not completely related to infectiousness, the removal of seropositive dogs leads to a significant reduction of canine and human incidence, 3) improvement of the sensitivity of the diagnostic tool used for canine control should optimize the efficacy of control, and 4) although difficult and expensive, the public health dog control campaigns performed in Brazil reduced the incidence of ZVL and should be maintained since treatment of dogs is an unrealistic intervention, both because of its prohibitive cost and relatively poor effectiveness.


Subject(s)
Dog Diseases/epidemiology , Leishmaniasis, Visceral/epidemiology , Zoonoses/epidemiology , Animals , Brazil/epidemiology , DDT/therapeutic use , Dog Diseases/drug therapy , Dogs , Humans , Leishmaniasis, Visceral/prevention & control , Leishmaniasis, Visceral/veterinary , Risk Factors
4.
Vaccine ; 17(20-21): 2554-61, 1999 Jun 04.
Article in English | MEDLINE | ID: mdl-10418902

ABSTRACT

The FML antigen of Leishmania donovani in combination with saponin, aluminum hydroxide (Al(OH)3) and Freund's incomplete adjuvant (FIA) was used in vaccines tested in an outbred murine model of visceral leishmaniasis, either through intraperitoneal or subcutaneous routes. The humoral response was significantly higher in the groups treated with FML + saponin or FML + Al(OH)3 than in controls, both before and after the infection. Animals immunized by the i.p. route developed higher antibody titres. A significant and specific reduction of parasitic load in relation to saline (85%, p < 0.01) and saponin (p < 0.025) controls, was seen in animals treated with FML + saponin by the i.p. Coincidentally with this reduction, an increase in antibodies of the IgG2a subtype was detected only in animals treated with FML + saponin i.p. A reduction of 88% in parasitic load was achieved by the combination of FML + Al(OH)3 (s.c.), but the Al(OH)3 treatment itself accounted for 68% of this protection. In our conditions, vaccination with FML + saponin i.p. was superior to other treatments and had no toxic effect due to saponin.


Subject(s)
Antigens, Protozoan/immunology , Leishmania donovani/immunology , Leishmaniasis, Visceral/prevention & control , Protozoan Vaccines/immunology , Aluminum Hydroxide/administration & dosage , Animals , Female , Immunoglobulin G/blood , Immunoglobulin G/classification , Immunoglobulin M/blood , Liver/parasitology , Mice , Protozoan Vaccines/administration & dosage , Saponins/administration & dosage , Vaccination
5.
Vaccine ; 15(9): 1024-9, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9261952

ABSTRACT

An 87.7% (P < 0.01) and 84% (P < 0.001) of protection against visceral leishmaniasis was achieved in CB hamsters and Balb/c mice, respectively, with saponin combined to the fucose-mannose ligand of Leishmania donovani (FML). However, an undesirable haemolytic effect was described for several saponins. Aiming to improve the formulation with FML/saponin, we comparatively analysed the haemolytic potential of recently characterized plant saponins and currently used adjuvants. The haemolytic activity of steroidic saponins from Agave sisalana; Smilax officinalis as well as commercial saponin (Riedel De Haën's), was higher than that of triterpenoid ones (Bredemeyera floribunda; Periandra mediterranea) and the Freund's complete adjuvant. The concentration resulting in 50% haemolysis was 500 micrograms ml-1 for aluminum hydroxide. The low haemolytic effect of P. mediterranea saponin was abolished by removal of its glycidic moiety and its sapogenin fraction as well as the Freund's Incomplete Adjuvant were non-haemolytic within this range. Furthermore, the adjuvant effect of three doses of P. mediterranea saponin injected with the FML antigen of L. donovani, was assayed in mice, either by the intraperitoneal (i.p.) or the subcutaneous (s.c.) route. The anti-FML IgG antibody levels increased and detectable levels were observed up to 3 months in the s.c. group. The response was expanded in both groups after an injection with a fourth vaccine dose. The IgG response showed increased levels of IgG2a only in the i.p. group, while IgG2b and IgG1 but not IgG3 antibodies were higher than controls in both groups. In conclusion, the results suggest that the recently described triterpenoid fractions of P. mediterranea can be safely used as adjuvant with low or non-haemolytic effect.


Subject(s)
Adjuvants, Immunologic/toxicity , Antigens, Protozoan/immunology , Fucose/immunology , Hemolysin Proteins/toxicity , Lectins/immunology , Leishmania donovani/immunology , Mannose/immunology , Saponins/immunology , Adult , Animals , Antibodies, Protozoan/biosynthesis , Antibodies, Protozoan/drug effects , Antibodies, Protozoan/immunology , Cricetinae , Fucose/metabolism , Humans , Lectins/toxicity , Leishmaniasis, Visceral/immunology , Leishmaniasis, Visceral/prevention & control , Ligands , Mannose/metabolism , Mice , Mice, Inbred BALB C , Plant Extracts/toxicity , Saponins/toxicity
6.
Rev Soc Bras Med Trop ; 29(2): 153-63, 1996.
Article in English | MEDLINE | ID: mdl-8713607

ABSTRACT

The Fucose-Mannose Ligand (FML) of Leishmania donovani is a complex glycoproteic fraction. Its potential use as a tool for diagnosis of human visceral leishmaniasis was tested with human sera from Natal, Rio Grande do Norte, Brazil. The FML-ELISA test, showed 100% sensitivity and 96% specificity, identifying patients with overt kala-azar (p < 0.001, when compared to normal sera), and subjects with subclinical infection. More than 20% apparently healthy subjects with positive reaction to FML developed overt kala-azar during the following 10 months. In the screening of human blood donnors, a prevalence of 5% of sororeactive subjects was detected, attaining 17% in a single day. The GP36 glycoprotein of FHL is specifically reconized by human kala-azar sera. The immunoprotective effect of FML on experimental L. donovani infection was tested in swiss albino mice. The protection scheemes included three weekly doses of FML, supplemented or not with saponin by the subcutaneous or intraperitoneal routes and challenge with 2 x 10(7) amastigotes of Leishmania donovani. An enhancement of 80.0% in antibody response (p < 0.001) and reduction of 85.5% parasite liver burden (p < 0.001) was detected in animals immunized with FML saponin, unrespectively of the immunization route.


Subject(s)
Antigens, Protozoan/analysis , Leishmania donovani/immunology , Leishmaniasis, Visceral/diagnosis , Protozoan Proteins/analysis , Animals , Blood Donors , Brazil/epidemiology , Chagas Disease/immunology , Enzyme-Linked Immunosorbent Assay , Female , Fucose/analysis , Humans , Leishmania donovani/chemistry , Leishmaniasis, Visceral/epidemiology , Leishmaniasis, Visceral/immunology , Leishmaniasis, Visceral/prevention & control , Ligands , Mannose/analysis , Mice , Vaccination
7.
Rev. paul. pediatr ; 9(34): 95-8, jul. 1991.
Article in Portuguese | LILACS | ID: lil-224419

ABSTRACT

Devido ao amplo espectro antimicrobiano e seu esquema de dose única diária, a ceftriaxona tem sido largamente usada para o tratamento de infecçöes graves, incluindo meningite bacteriana. Entre os importantes problemas enfrentados por médicos e pacientes em países desenvolvidos, estäo a falta de leitos hospitalares e a alta incidência de hospitalares. Por estas razöes e baseados em nossa experiência prévia com o uso de ceftriaxona, decidimos estudar a possibilidade de um regime terapêutico que permitisse tratamento ambulatorial de pacientes com meningite bacteriana. Vinte crianças com idades variando entre 3 e 75 meses e com diagnóstico de meningite bacteriana causada por N. meningitidis, S. pneumoniae ou H. influenzae, foram tratadas com dose única...


Subject(s)
Humans , Female , Male , Infant , Child, Preschool , Child , Ceftriaxone/administration & dosage , Meningitis, Bacterial/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...